Document is current
Any future updates will be listed below
-
Authors
Hirose, Takahisa
Saitoh, Chihiro
Oikawa, Ichiro
Kondo, Nobuo
-
Funding
Funding for this research was provided by:
EA Pharma Co., Ltd.
- License Information
-
More Information
Article History
Received: 27 June 2017
Accepted: 12 December 2017
First Online: 12 January 2018
Compliance with ethical standards
:
: T. Hirose received consultancy fees from EA Pharma Co., Ltd.; lecture fees from MSD K.K., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Ltd., Novartis Pharma K.K., Dainippon Sumitomo Pharma Co., Ltd., Novo Nordisk Pharma Ltd, Sanofi K.K., AstraZeneca K.K., and Daiichi Sankyo Co., Ltd.; and research funds from MSD K.K., Eli Lilly Japan K.K., Takeda Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd, Kissei Pharmaceutical Co., Ltd., Boehringer Ingelheim, Mitsubishi Tanabe Pharma Corporation, Dainippon Sumitomo Pharma Co., Ltd., Sanofi K.K., Ono pharmaceutical Co., Ltd., AstraZeneca K.K., and Daiichi Sankyo Co., Ltd. C. Saitoh and I. Oikawa are employees of EA Pharma Co., Ltd. N. Kondo was an employee of EA Pharma Co., Ltd.
: This research involves human participants. The study protocol was approved by the Sakayori Clinic Institutional Review Board on July 23, 2012 (approval number is not applicable).
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.
: Informed consent was obtained from all patients for being included in the study.
